| Net Income/(Loss) per Share |
Net Income (Loss) per ShareThe following table presents the reconciliation of net income (loss) to net loss used in computing basic and diluted net income (loss) per share of Common Stock attributable to common stockholders: | | | | | | | | | | | | | March 31, 2023 | | March 31, 2022 | | Net income (loss) used in computing basic net income (loss) per share of Common Stock attributable to common stockholders | $ | 6,487 | | | $ | (153,098) | | | Less: Dilutive impact of SPA Warrants | (11,897) | | | — | | | Less: Dilutive impact of conversion of SPA notes and settlement of make-whole provisions | (59,331) | | | — | | | Net loss used in computing diluted net loss per share of Common Stock attributable to common stockholders | $ | (64,741) | | | $ | (153,098) | |
The following table presents the reconciliation of basic to diluted weighted average shares used in computing net income/(loss) per share of Common Stock attributable to common stockholders. In computing the weighted average shares using the “if-converted” method in accordance with ASC 260-10, Earning per Share the Company uses the average Interest Conversion Price during the three months ended March 31, 2023. | | | | | | | | | | | | | March 31, 2023 | | March 31, 2022 | | Weighted average shares used in computing net income per share of common stock, basic | 657,565,442 | | | 322,211,392 | | | Add: Shares issuable upon exercise of SPA Warrants | 19,121,103 | | | — | | | Add: Shares issuable upon conversion of SPA notes and settlement of make-whole provisions | 311,952,117 | | | — | | | Weighted average shares used in computing net loss per share of common stock, diluted | 988,638,662 | | | 322,211,392 | |
The following table presents the potentially dilutive shares that were excluded from the computation of diluted net income (loss) per share of Common Stock attributable to common stockholders, because their effect was anti-dilutive: | | | | | | | | | | | | | March 31, 2023 | | March 31, 2022 | | Shares issuable upon exercise of SPA Warrants, excluding amounts included above in Diluted EPS | 45,571,419 | | | — | | | Shares issuable upon conversion of notes and settlement of Make-Whole provisions, excluding amounts included above in Diluted EPS | — | | | 9,009,210 | | | Other warrants | 29,454,593 | | | 4,544,258 | | | Stock-based compensation awards – Options | 37,181,872 | | | 43,781,815 | | | Stock-based compensation awards – RSUs | 20,131,111 | | — | | | Public warrants | 23,540,988 | | | 22,977,568 | | | Private warrants | 111,131 | | | 674,551 | | | Total | 155,991,114 | | | 80,987,402 | |
|